1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63


Real-time Estimate Cboe Europe  -  10:11 2022-08-08 am EDT
1656.20 GBX   -0.65%
05:43aUBS Keeps GSK At Neutral, Trims PT
04:43aGSK : Ubs cuts target price to 1820p from 1860p…
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK completes acquisition of Sierra Oncology

07/01/2022 | 12:20pm EDT

GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.

As previously announced, the acquisition of Sierra Oncology includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anaemia. In addition, momelotinib complements GSK's Blenrep (belantamab mafodotin); the acquisition builds on the company's expertise in haematology and aligns with GSK's strategy of building a strong portfolio of specialty medicines and vaccines. If approved, momelotinib will contribute to GSK's growing specialty medicines business, with a US launch anticipated in 2023.

Luke Miels, Chief Commercial Officer, GSK, said: "This acquisition expands our innovative oncology portfolio, demonstrating our commitment to improving patient outcomes and creating value for shareholders. We now have a late-stage differentiated molecule in momelotinib, which could potentially address a significant unmet need in myelofibrosis patients with anaemia. Our focus is now on execution."

In June 2022, Sierra Oncology presented the complete data from the MOMENTUM phase III trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anaemia. Sierra Oncology submitted a New Drug Application to the US Food and Drug Administration in June, and GSK anticipates a regulatory submission in Europe in the second half of 2022.

Financial considerations

Upon completion of the acquisition, GSK acquired all outstanding shares of Sierra Oncology for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.6 billion at current exchange rates). The per-share price represented a premium of approximately 39 per cent to Sierra Oncology's closing stock price on 12 April 2022 and approximately 63 per cent to Sierra's volume-weighted average price (VWAP) over the last 30 trading days.

About myelofibrosis

Myelofibrosis is a rare blood cancer that results from dysregulated JAK-STAT signalling and is characterised by constitutional symptoms, splenomegaly (enlarged spleen) and progressive anaemia. From prior studies with momelotinib, we know approximately half of myelofibrosis patients are moderately to severely anaemic when eligible for JAK inhibitor treatment. Furthermore, currently approved JAK inhibitors only address symptoms and splenomegaly and are myelosuppressive. This can lead to worsening anaemia, resulting in dose reductions that potentially reduce treatment effect.

Myelofibrosis affects approximately 20,000 patients in the US, with approximately 40% of patients already anaemic at time of diagnosis and nearly all patients estimated to eventually develop anaemia.[1],[2] Patients treated with the most commonly used JAK inhibitor will often require transfusions, and more than 30% will discontinue treatment due to anaemia.[3] Anaemia and transfusion dependence are strongly correlated with poor prognosis and shortened survival.[4]

About momelotinib

Momelotinib has a differentiated mode of action with inhibitory ability along three key signalling pathways: activin A receptor, type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase (JAK) 1, and JAK2. This activity may lead to beneficial treatment effects on anaemia and reduce transfusion dependence while treating myelofibrosis symptoms and splenic response.

GSK in oncology

GSK is focused on maximising patient survival through transformational medicines. GSK's pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody-drug conjugates and cell therapy, either alone or in combination.

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.


[1] Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. HemaSphere, 1(1), e1. https://doi.org/10.1097/HS9.0000000000000001

[2] Chifotides, H.T., Bose, P. & Verstovsek, S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15, 7 (2022). https://doi.org/10.1186/s13045-021-01157-4

[3] Palandri, F., Palumbo, G.A., Elli, E.M. et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 11, 4 (2021). https://doi.org/10.1038/s41408-020-00392-1

[4] Pardanani, A., & Tefferi, A. (2011). Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. Haematologica, 96(1), 8-10. https://doi.org/10.3324/haematol.2010.035519


(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC -0.53% 1657.4 Delayed Quote.1.42%
All news about GSK PLC
05:43aUBS Keeps GSK At Neutral, Trims PT
04:43aGSK : Ubs cuts target price to 1820p from 1860p…
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
08/05UK Financial Watchdog Fines Ex-ConvaTec Chair For Sharing Inside Information
08/05GSK : Morgan stanley resumes coverage with equal weight; target p…
08/03European ADRs Nudge Higher in Wednesday Trading
08/03GLAXOSMITHKLINE : GSK Announces Offer to Repurchase Exchangeable Senior Notes Due 2023 - F..
08/03GSK Offers to Buy Back $280 Million of 2023 Notes
08/03GSK Announces Offer To Repurchase Exchangeable Senior Notes Due 2023
08/03Gsk - its wholly owned unit, gsk finance plc, is offering to rep…
More news
Analyst Recommendations on GSK PLC
More recommendations
Sales 2022 29 992 M 36 125 M 36 125 M
Net income 2022 4 410 M 5 312 M 5 312 M
Net Debt 2022 15 846 M 19 086 M 19 086 M
P/E ratio 2022 15,4x
Yield 2022 3,43%
Capitalization 67 485 M 81 285 M 81 285 M
EV / Sales 2022 2,78x
EV / Sales 2023 2,61x
Nbr of Employees 90 096
Free-Float 93,6%
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 667,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 22,3%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC1.42%81 285
JOHNSON & JOHNSON0.02%449 879
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068